ARS Investment Partners LLC Raises Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

ARS Investment Partners LLC lifted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 265,480 shares of the biotechnology company’s stock after purchasing an additional 2,369 shares during the period. Ascendis Pharma A/S comprises 3.3% of ARS Investment Partners LLC’s investment portfolio, making the stock its 7th largest holding. ARS Investment Partners LLC’s holdings in Ascendis Pharma A/S were worth $36,549,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ASND. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. Groupama Asset Managment acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $60,000. GAMMA Investing LLC boosted its stake in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares during the last quarter. Signaturefd LLC lifted its holdings in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the period. Finally, Rhumbline Advisers boosted its position in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares during the last quarter.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $128.13 on Tuesday. The stock has a market capitalization of $7.78 billion, a price-to-earnings ratio of -15.86 and a beta of 0.65. The business’s fifty day moving average is $133.12 and its 200-day moving average is $133.43. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Wedbush restated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. TD Cowen decreased their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Finally, Oppenheimer dropped their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $192.07.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.